HILDEN, Germany & GERMANTOWN, Md.–()–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the launch of its QuantiFERON SARS-CoV-2 RUO solution that can detect T-cell responses of the human immune system to the pathogen that causes COVID-19, which could help researchers find out more about immunity levels and disease progression.

Studies suggest that T-cell response to SARS-CoV-2 declines much more slowly than antibody response, which presents several benefits to researchers who want to push beyond the existing detection of active infections to screen for potential courses of the illness and long-term immune responses to it. QIAGEN’s QuantiFERON SARS-CoV-2 Research Use Only (RUO) solution could be a valuable tool in this research.

There is also growing evidence that T-cell response gives a reliable indication of how severe the course of an illness triggered by SARS-CoV-2 will be in infected patients, and how immune those who have recovered remain months – possibly even years – after having been infected.

QuantiFERON SARS-CoV-2 RUO is a flexible, modular system designed to meet a wide range of research demands. It is based on QIAGEN’s easy-to-use QuantiFERON technology, pioneered in the QuantiFERON-TB Gold Plus test for latent tuberculosis and recognized worldwide for its ability to detect interferon gamma that T-cells release upon contact with certain pathogens.

Read the full article at: www.businesswire.com

The following two tabs change content below.
Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.